Ethnic Variations in Antidepressant Response
This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication [citalopram (Celexa®)].
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Ethnic Variations in Antidepressant Response|
- Hamilton Rating Scale for Depression [ Time Frame: Measured weekly for 11 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||June 2002|
|Study Completion Date:||November 2006|
|Primary Completion Date:||November 2006 (Final data collection date for primary outcome measure)|
Active Comparator: Citalopram
All subjects receive an FDA approved dose of Citalopram
PDA Approved antidepressant
Depressed patients vary substantially in their responses to antidepressants. Genetic factors may account for a large part of these differences in response. This study will include both African Americans and Caucasians to examine the role of genetic factors in treatment response.
Participants receive citalopram (Celexa) for 8 weeks and a placebo for 1 week. Visits occur once a week for 11 weeks. A variety of interviews, scales, tests, and questionnaires are used to assess participants.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00047671
|United States, California|
|Cedars-Sinai Medical Center, Department of Psychiatry, Clinical Trials Unit|
|Los Angeles, California, United States, 90048|
|Los Angeles, California, United States, 90059|
|Harbor-UCLA Medical Center|
|Torrance, California, United States, 90502|